STOCKHOLM, Sweden — New data on clazakizumab, a monoclonal antibody targeting interleukin-6 (IL-6), and home hemodialysis suggest the potential of two ways to reduce the high risk for cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results